Stroke and bleeding risk assessment: Where are we now?

Journal of Atrial Fibrillation

Volumn 6, Issue 6, 2014, Pages 49-57

  Dzeshka, Mikhail S ^a,b   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b GRODNO STATE MEDICAL UNIVERSITY   (Belarus)

Author keywords

AtrialFibrillation; Bleeding; Risk assessment; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; BIOLOGICAL MARKER; NONSTEROID ANTIINFLAMMATORY AGENT;

BLEEDING; CEREBROVASCULAR ACCIDENT; CHA2DS2 VASC SCORE; CHADS2 SCORE; CONGESTIVE HEART FAILURE; DECISION MAKING; DIABETES MELLITUS; DISEASE PREDISPOSITION; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; KIDNEY DISEASE; LIVER DYSFUNCTION; MEDICAL HISTORY; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; THROMBOSIS PREVENTION; VASCULAR DISEASE;

EID: 84901594613     PISSN: None     EISSN: 19416911     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285(18): 2370-2375. (Pubitemid 32424106)
2. Björck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke. 2013; 44(11): 3103-3108.
3. Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, Goette A, Hindricks G, Hohnloser S, Kappenberger L, Kuck KH, Lip GY, Olsson B, Meinertz T, Priori S, Ravens U, Steinbeck G, Svernhage E, Tijssen J, Vincent A, Breithardt G. Outcome parameters for trials in atrial fibrillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur. Heart J. 2007; 28(22): 2803-2817. (Pubitemid 350135529)
4. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Europace. 2012; 14(10): 1385-1413.
5. Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane D, Levi M, Marin F, Palareti G, Kirchhof P; European Heart Rhythm Association. Bleeding risk assessment and management in atrial fibrillation patients. Executive summary of a position document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] working group on thrombosis. Thromb. Haemost. 2011; 106(6): 997-1011.
6. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann. Intern. Med. 2009; 151(5): 297-305.
7. Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, Rauns J, Tolstrup JS, Hansen PR, Gislason GH, Torp-Pedersen C. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb. Haemost. 2011; 106(4): 739-749.
8. Lip GY. Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why? Eur. Heart J. 2013; 34(14): 1041-1049.
9. Lip GY. Stroke in atrial fibrillation: epidemiology and thromboprophylaxis. J. Thromb. Haemost. 2011; 9 (Suppl. 1): 344-351.
10. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG, ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur. Heart J. 2001; 22(20): 1852-1923. (Pubitemid 33061598)
11. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest. 2001; 119 (1 Suppl): 194S-206S. (Pubitemid 32154200)
12. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126 (Suppl. 3): 429S-456S. (Pubitemid 39302603)
13. Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D'Agostino RB, Larson MG, Kannel WB, Benjamin EJ. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003; 290(8): 1049-1056. (Pubitemid 37430445)
14. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA. 2001; 285(22): 2864-2870. (Pubitemid 32537350)
15. Taylor JMG, Yu M. Bias and efficiency loss due to categorizing an explanatory variable. J. Multivariate Anal. 2002; 83(1): 248-263.
16. Ragland DR. Dichotomizing continuous outcome variables: dependence of the magnitude of association and statistical power on the cutpoint. Epidemiology. 1992; 3(5): 434-440.
17. Austin PC, Brunner LJ, Austin PC, Brunner LJ. Inflation of the type I error rate when a continuous confounding variable is categorized in logistic regression analyses. Stat. Med. 2004; 23(7): 1159-1178. (Pubitemid 38477073)
18. Wilke T, Groth A, Mueller S, Pfannkuche M, Verheyen F, Linder R, Maywald U, Kohlmann T, Feng YS, Breithardt G, Bauersachs R. Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb. Haemost. 2012; 107(6): 1053-1065.
19. Kirchhof P, Nabauer M, Gerth A, Limbourg T, Lewalter T, Goette A, Wegscheider K, Treszl A, Meinertz T, Oeff M, Ravens U, Breithardt G, Steinbeck G; AFNET registry investigators. Impact of the type of centre on management of AF patients: surprising evidence for differences in antithrombotic therapy decisions. Thromb. Haemost. 2011; 105(6): 1010-1023.
20. Nieuwlaat R, Capucci A, Lip GY, Olsson SB, Prins MH, Nieman FH, Lopez-Sendon J, Vardas PE, Aliot E, Santini M, Crijns HJ. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on atrial fibrillation. Eur. Heart J. 2006; 27(24): 3018-3026. (Pubitemid 44963431)
21. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 2007; 146: 857-867. (Pubitemid 351650486)
22. van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD, Koudstaal PJ, Petersen P, Perez-Gomez F, Knottnerus JA, Boode B, Ezekowitz MD, Singer DE. Effect of age on stroke prevention therapy in patients with atrial fibrillation. Stroke. 2009; 40(4): 1410-1416.
23. Lee BH, Park JS, Park JH, Kwak JJ, Hwang ES, Kim SK, Choi DH, Kim YH, Pak HN. The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1. J Cardiovasc. Electrophysiol. 2010; 21(5): 501-507.
24. Gorin L, Fauchier L, Nonin E, de Labriolle A, Haguenoer K, Cosnay P, Babuty D, Charbonnier B. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1. Thromb. Haemost. 2010; 103(4): 833-840.
25. Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH, Ioachim PM, Tica O, Boriani G, Cimaglia P, Diemberger I, Hellum CF, Mortensen B, Maggioni AP, 'Real-world' antithrombotic treatment in atrial fibrillation: the EURObservational Research Programme Atrial Fibrillation General Pilot survey. Am. J. Med. 2014. doi: 10.1016/j.amjmed.2013.12.022. [Epub ahead of print].
26. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007; 69(6): 546-554.
27. Pisters R, Lane DA, Marin F, Camm AJ, Lip GY. Stroke and thromboembolism in atrial fibrillation. Circ. J. 2012; 76(10): 2289-2304.
28. Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, Petersen P. Selecting patients with atrial fibrillation for anticoagulation: Stroke risk stratification in patients taking aspirin. Circulation. 2004; 110(16): 2287-2292. (Pubitemid 39407328)
29. Fang MC, Go AS, Chang Y, Borowsky L, Pomernacki NK, Singer DE. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J. Am. Coll. Cardiol. 2008; 51(8): 810-815. (Pubitemid 351253746)
30. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010; 137(2): 263-272.
31. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GY. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence based Clinical Practice Guidelines. Chest. 2012; 141 (2 Suppl.): e531S-e575S.
32. Skanes A, Healey J, Cairns J, Dorian P, Gillis AM, McMurtry S, Mitchell LB, Verma A, Nattel S. Focused 2012 update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: recommendations for stroke prevention and rate/rhythm control. Can. J. Cardiol. 2012; 28(2): 125-136.
33. Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb. Haemost. 2012; 107(6): 1172-1179.
34. Van Staa TP, Setakis E, Di Tanna GL, Lane DA, Lip GY. A comparison of risk stratification schema for stroke in 79884 atrial fibrillation patients in general practice. J. Thromb. Haemost. 2011; 9(1): 39-48.
35. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur. Heart J. 2010; 31(19): 2369-2429.
36. Keogh C, Wallace E, Dillon C, Dimitrov BD, Fahey T. Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis. Thromb. Haemost. 2011; 106(3): 528-538.
37. Karthikeyan G, Eikelboom JW. The CHADS2 score for stroke risk stratification in atrial fibrillation - friend or foe? Thromb. Haemost. 2010; 104(1): 45-48.
38. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: The Swedish Atrial Fibrillation cohort study. Eur. Heart J. 2012; 33(12): 1500-1510.
39. Lin LY, Lee CH, Yu CC, Tsai CT, Lai LP, Hwang JJ, Chen PC, Lin JL. Risk factors and incidence of ischaemic stroke in Taiwanese with nonvalvular atrial fibrillation - a nationwide database analysis. Atherosclerosis. 2011; 217(1): 292-295.
40. Olesen JB, Fauchier L, Lane DA, Taillandier S, Lip GY. Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest. 2012; 141(1): 147-153.
41. Avgil Tsadok M, Jackevicius CA, Rahme E, Humphries KH, Behlouli H, Pilote L. Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. JAMA. 2012; 307(18): 1952-1958.
42. Mikkelsen AP, Lindhardsen J, Lip GY, Gislason GH, Torp-Pedersen C, Olesen JB. Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study. J. Thromb. Haemost. 2012; 10(9): 1745-1751.
43. Friberg L, Benson L, Rosenqvist M, Lip GY. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. BMJ. 2012; 344: e3522.
44. Olesen JB, Lip GY, Lane DA, Kober L, Hansen ML, Karasoy D, Hansen CM, Gislason GH, Torp-Pedersen C. Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study. Am. J. Med. 2012: 125: 826.e13-826.e23.
45. Davies M, Hobbs F, Davis R, Kenkre J, Roalfe AK, Hare R, Wosornu D, Lancashire RJ. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening Study: a population based study. Lancet. 2001; 358(9280): 439-444. (Pubitemid 32769849)
46. Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GY, Fauchier L. Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: The Loire Valley Atrial Fibrillation Project. Eur. J. Heart Fail. 2012; 14(3): 295-301.
47. Jang SJ, Kim MS, Park HJ, Han S, Kang DH, Song JK, Park SW, Park SJ, Kim JJ. Impact of heart failure with normal ejection fraction on the occurrence of ischaemic stroke in patients with atrial fibrillation. Heart. 2013; 99(1): 17-21.
48. Potpara TS, Polovina MM, Licina MM, Marinkovic JM, Prostran MS, Lip GY. Reliable identification of 'truly low' thromboembolic risk in patients initially diagnosed with 'lone' atrial fibrillation: the Belgrade Atrial Fibrillation Study. Circ. Arrhythm. Electrophysiol. 2012; 5(2): 319-326.
49. Abu-Assi E, Otero-Ravina F, Allut Vidal G, Coutado Méndez A, Vaamonde Mosquera L, Sánchez Loureiro M, Caneda Villar MC, Fernández Villaverde JM, Maestro Saavedra FJ, González-Juanatey JR; on behalf of Grupo Barbanza researchers. Comparison of the reliability and validity of four contemporary risk stratification schemes to predict thromboembolism in non-anticoagulated patients with atrial fibrillation. Int. J. Cardiol. 2013; 166(1): 205-209.
50. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investications of antihemostatic medicinal products in non-surgical patients. J. Thromb. Haemost. 2005; 3(4): 692-694. (Pubitemid 41647882)
51. Flaherty ML, Kissela B, Woo D, Kleindorfer D, Alwell K, Sekar P, Moomaw CJ, Haverbusch M, Broderock JP. The increasing incidence of anticoagulant- associated intracerebral hemorrhage. Neurology. 2007; 68(2): 116-121. (Pubitemid 46071894)
52. Roskell NS, Samuel M, Noack H, Monz BU. Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies. Europace. 2013; 15(6): 787-797.
53. Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane D, Levi M, Marin F, Palareti G, Kirchhof P; Document reviewers: Collet JP, Rubboli A, Poli D, Camm J. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace. 2011; 13(5): 723-746.
54. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, Radford MJ. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am. Heart J. 2006; 151(3): 713-719. (Pubitemid 43290267)
55. Jorgensen AL, FitzGearald RJ, Oyee J, Pirmohamed M, Williamson PR. Influence of CYP2C9 and VKORC1 on patients response to warfarin: a systematic review and meta-analysis. PLoS One. 2012; 7(8): e44064.
56. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138(5): 1093-1100.
57. Olesen JB, Lip GY, Hansen PR, Lindhardsen J, Ahlehoff O, Andersson C, Weeke P, Hansen ML, Gislason GH, Torp-Pedersen C. Bleeding risk in 'real world' patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. J. Thromb. Haemost. 2011; 9(8): 1460-1467.
58. Lip GY, Banerjee A, Lagrenade I, Lane DA, Taillandier S, Fauchier L. Assessing the risk of bleeding in patients with atrial fibrillation: The Loire Valley Atrial Fibrillation Project. Circ. Arrhythm. Electrophysiol. 2012; 5(5): 941-948.
59. Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY. Performance of the Hemorr(2)hages, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: The AMADEUS (evaluating the use of sr34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) Study. J. Am. Coll. Cardiol. 2012; 60(9): 861-867.
60. Overvad TF, Larsen TB, Albertsen IE, Rasmussen LH, Lip GY. Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation. Expert Rev. Cardiovasc. Ther. 2013; 11(12): 1619-1629.
61. Lip GY, Lin HJ, Hsu HC, Su TC, Chen MF, Lee YT, Chien KL. Comparative assessment of the HAS-BLED score with other published bleeding risk scoring schemes, for intracranial haemorrhage risk in a non-atrial fibrillation population: the Chi-Shan Community Cohort Study. Int. J. Cardiol. 2013; 168(3): 1832-1836.
62. Omran H, Bauersachs R, Rubenacker S, Goss F, Hammerstingl C. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the National Multicentre BNK Online Bridging Registry (BORDER). Thromb. Haemost. 2012; 108: 65-73.
63. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J. Am. Coll. Cardiol. 2011; 58(4): 395-401.
64. Roldán V, Marín F, Fernández H, Manzano-Fernandez S, Gallego P, Valdés M, Vicente V, Lip GY. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy. Chest. 2013; 143(1): 179-184.
65. Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb. Haemost. 2011; 106(5): 968-977.
66. Gallego P, Roldan V, Marin F, Romera M, Valdes M, Vicente V, Lip GY. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb. Haemost. 2013; 110(6): 1189-1198.
67. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ; RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010; 376(9745): 975-983.
68. Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb. Res. 2009; 124(1): 37-41.
69. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest. 2013; 144(5): 1555-1563.
70. Lip GYH, Haguenoer K, Saint-Etienne C, Fauchier L. Relationship of the SAMe-TT2R2 score to poor quality anticoagulation, stroke, clinically relevant bleeding and mortality in patients with atrial fibrillation. Chest. 2014.
71. Apostolakis S, Lane DA, Buller H, Lip GY. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial. Thromb. Haemost. 2013; 110(5): 1074-1079.
72. Lip GY, Lane DA, Buller H, Apostolakis S. Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: The AMADEUS Study. Chest. 2013; 144(6): 1839-1847.
73. Banerjee A, Fauchier L, Bernard-Brunet A, Clementy N, Lip GY. Composite risk scores and composite endpoints in the risk prediction of outcomes in anticoagulated patients with atrial fibrillation. The Loire Valley Atrial Fibrillation Project. Thromb Haemost. 2014; 111(3). [Epub ahead of print].
74. Christiansen CB, Lip GY, Lamberts M, Gislason G, Torp-Pedersen C, Olesen JB. Retinal vein and artery occlusions: a risk factor for stroke in atrial fibrillation. J. Thromb. Haemost. 2013; 11(8): 1485-1492.
75. Mead GE, Lewis SC, Wardlaw JM, Dennis MS. Comparison of risk factors in patients with transient and prolonged eye and brain ischemic syndromes. Stroke. 2002; 33(10): 2383-2390.
76. Wanahita N, Messerli FH, Bangalore S, Gami AS, Somers VK, Steinberg JS. Atrial fibrillation and obesity - results of a meta-analysis. Am. Heart J. 2008; 155(2): 310-315.
77. Dublin S, French B, Glazer NL, Wiggins KL, Lumley T, Psaty BM, Smith NL, Heckbert SR. Risk of new-onset atrial fibrillation in relation to body mass index. Arch. Intern. Med. 2006; 166(21): 2322-2328. (Pubitemid 44833356)
78. Strazzullo P, D'Elia L, Cairella G, Garbagnati F, Cappucio FP, Scalfi L. Excess body weight and incidence of stroke: meta-analysis of prospective studies with 2 million participants. Stroke. 2010; 41(5): e418-e426.
79. Overvad TF, Rasmussen LH, Skjøth F, Overvad K, Lip GY, Larsen TB. Body mass index and adverse events in patients with incident atrial fibrillation. Am. J. Med. 2013; 126(7): 640.e9-640.e17.
80. Overvad TF, Rasmussen LH, Skjøth F, Overvad K, Albertsen IE, Lane DA, Lip GY, Larsen TB. Alcohol intake and prognosis of atrial fibrillation. Heart. 2013; 99(15): 1093-1099.
81. Albertsen IE, Rasmussen LH, Lane DA, Overvad TF, Skjoth F, Overvad K, Lip GY, Larsen TB. The impact of smoking on thromboembolism and mortality in patients with incident atrial fibrillation: insights from the Danish Diet, Cancer and Health study. Chest. 2013. doi: 10.1378/chest.13-1740. [Epub ahead of print].
82. Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: An Asian perspective. Thromb. Haemost. 2014; 111(5). [Epub ahead of print].
83. Tse HF, Wang YJ, Ahmed Ai-Abdullah M, Pizarro-Borromeo AB, Chiang CE, Krittayaphong R, Singh B, Vora A, Wang CX, Zubaid M, Clemens A, Lim P, Hu D. Stroke prevention in atrial fibrillation - an Asian stroke perspective Heart Rhythm. 2013; 10(7): 1082-1088.
84. Wang C, Yang Z, Wang C, Wang Y, Zhao X, Liu L, Wang DZ, Li H, Wang Y. Significant Underuse of Warfarin in Patients with Nonvalvular Atrial Fibrillation: Results from the China National Stroke Registry. J. Stroke Cerebrovasc. Dis. 2013. doi: 10.1016/j.jstrokecerebrovasdis.2013.10.006. [Epub ahead of print].
85. Hippisley-Cox J, Coupland C, Brindle P. Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. BMJ. 2013; 346: f2573.
86. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke prevention in Atrial Fibrillation III Investigators. J. Am. Coll. Cardiol. 1998; 31(7): 1622-1626. (Pubitemid 28273307)
87. SPAF-Investigators. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The stroke prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Ann. Intern. Med. 1998; 128(8): 639-647.
88. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Prognostic value of plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation. 2003; 107(25): 3141-3145. (Pubitemid 36793082)
89. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation. 2002; 106(15): 1962-1967. (Pubitemid 35176302)
90. Mahe I, Drouet L, Simoneau G, Minh-Muzeaux S, Caulin C, Bergmann JF. D-dimer can predict survival in patients with chronic atrial fibrillation. Blood Coagul. Fibrinolysis 2004; 15(5): 413-417. (Pubitemid 38901612)
91. Vene N, Mavri A, Kosmelj K, Stegnar M. High d-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb. Haemost. 2003; 90: 1163-1172. (Pubitemid 38004439)
92. Nakamura M, Koeda Y, Tanaka F, Onoda T, Itai K, Ohsawa M, Tanno K, Sakata K, Omama S, Ishibashi Y, Makita S, Ohta M, Ogasawara K, Komatsu T, Okayama A. Plasma B-type Natriuretic Peptide as a Predictor of Cardiovascular Events in Subjects with Atrial Fibrillation: A Community-Based Study. PLoS One. 2013; 8(12): e81243.
93. Tunon J, Blanco-Colio L, Cristobal C, Tarin N, Higueras J, Huelmos A, Alonso J, Egido J, Asensio D, Lorenzo O, Mahillo-Fernandez I, Rodriges-Artalejo F, Farre J, Martin-Ventura JL, Lopez-Bescos L. Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease. Am. J. Cardiol. 2014; 113(3): 434-440.
94. Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J. Am. Coll. Cardiol. 2011; 57(12): 1339-1348.
95. Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, Singer DE; ATRIA Study Investigators. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2009; 119(10): 1363-1369.
96. Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA, Lindhardsen J, Gislason GH, Torp-Pedersen C. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N. Engl. J. Med. 2012; 367(7): 625-635.
97. Ng KP, Edwards NC, Lip GY, Townend JN, Ferro CJ. Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation. Am. J. Kidney Dis. 2013; 62(3): 615-632.
98. Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, Patel MR, Mahaffey KW, Halperin JL, Breithardt G, Hankey GJ, Hacke W, Becker RC, Nessel CC, Fox KA, Califf RM; ROCKET AF Steering Committee and Investigators. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts. Circulation. 2013; 127(2): 224-232.
99. Apostolakis S, Lane DA, Banerjee A. Letter by Apostolakis et al regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts". Circulation. 2013; 128(11): e171.
100. Pisters R, Nieuwlaat R, Lane DA, Crijns HJ, Lip GY. Potential net clinicalbenefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey. Thromb Haemost. 2013 Feb;109(2):328-36.
101. Guo Y, Pisters R, Apostolakis S, Blann AD, Wang H, Zhao X, Zhang Y, Zhang D, Ma J, Wang Y, Lip GY. Stroke risk and suboptimal thromboprophylaxis in Chinese patients with atrial fibrillation: would the novel oral anticoagulants have an impact? Int J Cardiol. 2013 Sep 20;168(1):515-22.
102. Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 2012 Mar;107(3):584-9.